Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Novartis
Takeda
Massachusetts General Hospital
Gamida Cell ltd
M.D. Anderson Cancer Center
Novartis
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
University of Arizona
Novartis
Thomas Jefferson University
American University of Beirut Medical Center
Hospices Civils de Lyon
Novartis
Novartis
Shenzhen TargetRx, Inc.
Novartis
Novartis
Eulji University Hospital
Stanford University
University of Milano Bicocca
Masonic Cancer Center, University of Minnesota
American Regent, Inc.
St. Olavs Hospital
Fred Hutchinson Cancer Center
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
Thomas Jefferson University
Eulji University Hospital
Gruppo Italiano Malattie EMatologiche dell'Adulto
Novartis
Novartis
University of Campinas, Brazil
University of Liverpool
Ann & Robert H Lurie Children's Hospital of Chicago
Fred Hutchinson Cancer Center
Ascentage Pharma Group Inc.
Ann & Robert H Lurie Children's Hospital of Chicago
University Hospital, Antwerp
Novartis
Advice Pharma Group srl
Astellas Pharma Inc
M.D. Anderson Cancer Center
Stanford University
St. Petersburg State Pavlov Medical University
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Australasian Leukaemia and Lymphoma Group
Astex Pharmaceuticals, Inc.
University College, London
Pfizer